Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs
Ionis Pharmaceuticals (NASDAQ: IONS) reported second-quarter earnings earlier this week and then followed up on Friday with a disclosure that it's getting full rights back to two of its drugs, inotersen and IONIS-FB-LRx, after GlaxoSmithKline (NYSE: GSK) decided not to license them.
Metric
Q2 2017
Source: Fool.com
GSK plc ADR Stock
€36.00
-2.700%
GSK plc ADR is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
As a result the target price of 49 € shows a positive potential of 36.11% compared to the current price of 36.0 € for GSK plc ADR.
